



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/837,446
		Filing Date	April 17, 2001
		First Named Inventor	BUTCHER, EUGENE C.
		Art Unit	1643
Sheet 1 of 1	Examiner Name	MERTZ, PREMA MARIA	
	Attorney Docket Number	STAN-110CON	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PM		US- 6,488,930 B1	Dec. 3, 2002	Wu et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PM		HEINEMANN et al., BASOPHIL RESPONSES TO CHEMOKINES ARE REGULATED BY BOTH SEQUENTIAL AND COOPERATIVE RECEPTOR SIGNALING, The Journal of Immunology, 2000, p. 2224-7223	
		IMAI et al., THE T CELL-DIRECTED CC CHEMOKINE TARC IS A HIGHLY SPECIFIC BIOLOGICAL LIGAND FOR CC CHEMOKINE RECEPTOR 4, The Journal of Biological Chemistry, 1997, 272(23): 15036-15042	
		KUNA et al., RANTES, A MONOCYTE AND T LYMPHOCYTE CHEMOTACTIC CYTOKINE RELEASES HISTAMINE FROM HUMAN BASOPHILS, The Journal of Immunology, 1997, 149(2): 636-642	
		UGUCCIONI et al., HIGH EXPRESSION OF THE CHEMOKINE RECEPTOR CCR3 IN HUMAN BLOOD BASOPHILS ROLE IN ACTIVATION BY EOTAXIN, MCP-4, AND OTHER CHEMOKINES, J. Clin. Invest., 1997, 100(5): 1137-1143	

Examiner Signature	Prema Mertz	Date Considered	8/10/04
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.